PharmAla Unveils New MDMA Clinical Trial Tool for Researchers
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF) is a biotechnology firm dedicated to the research, development, and production of LaNeo™ MDMA and its innovative derivatives (MDXX class molecules). The company has introduced a new tool designed to give qualified researchers direct access to its Chemistry, Manufacturing, and Control (CMC) data, along with its investigator’s brochure.
Addressing the Surge in Research Requests
Recently, PharmAla has seen a notable rise in requests for documentation related to MDMA research materials. This increase is largely due to heightened interest from clinical researchers following recent regulatory changes regarding MDMA. CEO Nicholas Kadysh remarked, “MDMA is of significant interest to the global research community.” The launch of this tool is intended to streamline the process for researchers seeking grant funding, reflecting PharmAla’s dedication to regulatory transparency and support for clinical research.
Improved Access to Drug Quality Information
The newly introduced tool can be accessed at https://pharmala.ca/clinical-trials and enables researchers to directly review drug product quality information. This initiative is anticipated to ease the application process for clinical trials involving MDMA, thereby enhancing PharmAla’s sales pipeline within the clinical trial sector. Numerous researchers worldwide are already utilizing LaNeo MDMA in their clinical studies.
Change in Corporate Leadership
PharmAla Biotech is also excited to announce the appointment of Mr. William Avery, CPA, CA, as the new Chief Financial Officer of the Corporation, effective October 1. Mr. Avery has been serving as a financial advisor for PharmAla Biotech for over a month and brings a wealth of experience from his previous role as a partner at MNP, where he focused on innovative companies.
About PharmAla
PharmAla Biotech Holdings Inc. specializes in the research, development, and manufacturing of MDXX class molecules, including MDMA. The company is committed to meeting the global demand for clinical-grade MDMA to support clinical trials and facilitate commercial sales in select areas, while also pursuing the development of new drugs within this category. PharmAla is recognized as the exclusive provider of clinical-grade MDMA for patient therapies outside of clinical trials.
Research and Development Efforts
PharmAla’s research and development division has successfully completed proof-of-concept research across various intellectual property families, including ALA-002, its leading drug candidate. The company operates under principles that foster strong relationships with regulatory bodies, recognizing that genuine success in the psychedelics industry hinges on such collaborations.
For further inquiries, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is the purpose of PharmAla's new tool?
The new tool provides researchers with direct access to important Chemistry, Manufacturing, and Control (CMC) data and investigator brochures related to MDMA.
How will this tool benefit researchers?
This tool simplifies the application process for clinical trials, making it easier for researchers to obtain grant funding and access necessary information about MDMA.
Who is PharmAla's new Chief Financial Officer?
PharmAla has appointed Mr. William Avery, CPA, CA, as Chief Financial Officer. He has previously served as a financial advisor and has experience with publicly traded companies.
What kind of research is PharmAla involved in?
PharmAla is engaged in the research, development, and manufacturing of MDXX class molecules, with a particular focus on MDMA. They are also developing novel therapeutic drugs within this category.
What makes PharmAla unique in the MDMA market?
PharmAla stands out as the only company providing clinical-grade MDMA for patient treatments outside of clinical trials, addressing the global need for such materials.
